The Scottish Medicines Consortium (SMC) has approved Kite’s CAR T-cell therapy, Yescarta (axi-cel), for treating adult ...

Arcellx Inc, a biotechnology firm focused on cell therapy innovations, has announced impressive results from its studies on ...

Elsevier, a leader in information and analytics, has announced its support for The Pistoia Alliance in promoting safe and responsible AI adoption in drug discovery. This effort aims to address key AI ...

Johnson & Johnson has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved BALVERSA (erdafitinib) for treating adults with unresectable or metastatic ...

At Blueprint Medicines, we aim to make a significant difference in patients’ lives by solving critical medical problems. Since the company’s inception, we have focused on addressing the burden faced ...

AstraZeneca’s Andrea Mugan shares her unique perspectives on patients, experience, change and challenges ...

Tedros Adhanom Ghebreyesus, WHO Director-General, commented: “The fact that TB still kills and sickens so many people is an outrage, when we have the tools to prevent it, detect it and treat it. WHO ...

The two-year programme will use virtual reality technology to teach essential skills A £4.5m initiative has been launched to address the growing skills shortage in the UK’s medicines manufacturing ...

There are around 55,100 new prostate cancer cases in the UK every year HBC Immunology (HBCI) has announced that an oral formulation of its lead peptide “significantly augmented” the anti-tumour ...

The London hub is home to life sciences companies including Novartis, Engitix and invoX Pharma Vivan Therapeutics has signed a new five-year lease at White City Place, a biotech hub in London home to ...

Lundbeck has announced a significant step forward in its Focused Innovator strategy with the acquisition of Longboard Pharmaceuticals. This strategic deal, valued at approximately USD 2.6 billion, ...

New treatment option for patients with newly diagnosed multiple myeloma The European Commission has approved the subcutaneous (SC) formulation of DARZALEX (daratumumab) in combination with bortezomib, ...